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ABSTRACT 
 
Protein-protein interactions (PPIs) constitute an emerging class of targets for pharmaceutical 
intervention pursued by both industry and academia. Despite their fundamental role in many 
biological processes and diseases such as cancer, PPIs are still largely underrepresented in 
today‟s drug discovery. This dissertation describes novel computational approaches developed to 
facilitate the discovery/design of small-molecule inhibitors of PPIs, using the oncogenic c-
Myc/Max interaction as a case study. 
First, we critically review current approaches and limitations to the discovery of small-
molecule inhibitors of PPIs and we provide examples from the literature. 
Second, we examine the role of protein flexibility in molecular recognition and binding, 
and we review recent advances in the application of Elastic Network Models (ENMs) to 
modeling the global conformational changes of proteins observed upon ligand binding. The 
agreement between predicted soft modes of motions and structural changes experimentally 
observed upon ligand binding supports the view that ligand binding is facilitated, if not enabled, 
by the intrinsic (pre-existing) motions thermally accessible to the protein in the unliganded form. 
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Third, we develop a new method for generating models of the bioactive conformations of 
molecules in the absence of protein structure, by identifying a set of conformations (from 
different molecules) that are most mutually similar in terms of both their shape and chemical 
features. We show how to solve the problem using an Integer Linear Programming formulation 
of the maximum-edge weight clique problem. In addition, we present the application of the 
method to known c-Myc/Max inhibitors. 
Fourth, we propose an innovative methodology for molecular mimicry design. We show 
how the structure of the c-Myc/Max complex was exploited to designing compounds that mimic 
the binding interactions that Max makes with the leucine zipper domain of c-Myc. 
In summary, the approaches described in this dissertation constitute important 
contributions to the fields of computational biology and computer-aided drug discovery, which 
combine biophysical insights and computational methods to expedite the discovery of novel 
inhibitors of PPIs. 
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1.0  INTRODUCTION 
1.1 BACKGROUND AND SIGNIFICANCE 
Biological processes involve the concerted interaction of biomolecules, among which protein-
protein interactions (PPIs) play a central role. Knowing how biomolecular interactions enable 
biological processes helps researchers identify the underlying causes of diseases and ultimately 
develop targeted therapeutic strategies, like designing drugs to modulate the interaction between 
two proteins or the ligand-binding properties of a specific enzyme. 
The ubiquitous role of PPIs in mediating biological processes in the cell and their 
involvement in a large number of diseases, such as cancer [1-3], make them attractive targets for 
pharmaceutical intervention. Traditionally, however, it was largely believed that finding small-
molecule drugs to modulate PPIs would be nearly impossible, as protein-protein interfaces are 
generally large and devoid of well-defined cavities that can accommodate a small molecule ‒ 
like those typically found on enzymes [4,5]. This view is perhaps reflected on the fact that most 
drugs approved by the Food and Drug Administration (FDA) target enzymes (kinases and 
proteases) and receptors (G-protein coupled receptors (GPCRs), ligand-gated ion channels and 
nuclear hormone receptors) [6]. Those „traditional‟ drug targets (i.e., enzymes and receptors) 
usually present large cavities to which endogenous small molecules bind, and the drugs are 
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designed to compete for those same sites, often replacing the endogenous ligand by a synthetic 
analog [6]. 
Despite the skepticism, an increasing number of scientific publications reporting the 
discovery of new potent small-molecule modulators of PPIs [4,5,7-10] have demonstrated the 
feasibility of targeting PPIs with small molecules. The perception that PPIs are „undruggable‟ 
has therefore changed; nowadays, PPIs are considered challenging but feasible drug targets 
offering great opportunities. 
Some important lessons can be learned from the past two decades of research. 
Mutagenesis and structural studies have shown that, within the large contact surfaces of PPIs, 
discrete pockets of stronger attractions, so-called „hotspots‟, comprise sites that can be targeted 
by small molecules [11]. Moreover, the plasticity of the protein interface, which in many cases 
adapts to binding different partners, provides the opportunity, upon binding of a ligand, for 
formation of new sub-pockets that may not be expected from the examnination of X-ray 
structures alone [12,13]. As discussed in Chapter 2.0 new drug discovery paradigms emerged 
(e.g., Fragment-Based Drug Discovery) and existing methodologies have been adapted to these 
paradigms to possibly increase productivity in drug discovery, particularly for those difficult 
targets like PPIs. 
Apart from the innumerous therapeutic applications, small-molecule modulators of PPIs 
also constitute valuable tools in Chemical Genetics studies, as probes to interrogate the function 
of PPIs participating in unknown biomolecular pathways or networks [14,15], which, in turn, 
facilitates the development of new targeted therapies. The ability to efficiently discover/design 
small-molecule modulators of PPIs is therefore of utmost importance to biomedical research. 
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This dissertation builds on and expands state-of-the-art computational methods, and 
proposes new protocols driven by biophysical insights, to accelerate the discovery of new 
inhibitors of PPIs. Two molecular modeling strategies are proposed: one based on known 
ligands, and the other based on the structure of the protein-protein complex. In addition, 
advances in modeling protein flexibility using Elastic Network Models are emphasized. As a 
study case, we apply the proposed strategies to design inhibitors of c-Myc/Max protein 
interaction, an important oncogenic target.  
1.2 TARGETING C-MYC/MAX INTERACTION FOR CANCER THERAPY 
c-Myc is a bHLH-Zip (basic Helix-Loop-Helix Leucine Zipper) transcription factor that 
regulates the expression of a large number of genes that collectively promote cell proliferation 
[16,17]. The active form of c-Myc exists as a heterodimer with another bHLH-Zip protein, Max 
[18-22]. The c-Myc/Max complex is necessary for transcriptional activation of target genes by 
binding the so-called Enhancer Box sites, “E-box” (CAC/GTG) on DNA [19,21,22] (Figure 1). 
 4 
 
Figure 1. Structure of the c-Myc/Max bHLHZip (basic Helix-Loop-Helix Leucine Zipper) dimerization 
domains bound to DNA. c-Myc green, Max yellow. PDB: 1NKP. 
c-Myc/Max participate in the so-called “Myc network” [18-22] (Figure 2). Opposing the 
effects of c-Myc/Max heterodimers are four additional closely related members termed the 
“Mad” family (Mad1, Mxi1, Mad3, and Mad4). Myc network members both positively and 
negatively regulate gene expression. c-Myc/Max heterodimers bind to the “E-box” of target 
genes and activate the expression of adjacent genes (+), via the N-terminal transactivation 
domain (TAD) of c-Myc [16,17]. The TAD recruits the large ATM/PI3-kinase-related protein 
TRRAP and associated histone acetylases (HAc). The resulting complex is believed to remodel 
adjacent chromatin, thus facilitating access by other transcription factors [19,21]. Mad/Max 
heterodimers compete for the same binding sites and repress transcription (-) through the 
formation of complexes containing the co-repressor mSin3 and associated histone deacetylases 
(HDAc) [19]. These complexes oppose the effect of c-Myc by de-acetylating chromatin and thus 
rendering it transcriptionally inactive. 
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Figure 2. The “Myc network” members both positively and negatively regulate gene expression. 
The fact that c-Myc promotes cell proliferation and is over-expressed in many cancer 
cells [23,24] makes it an attractive anti-cancer target [25]. Since all known functions of c-Myc 
are dependent on its ability to heterodimerize with Max, small-molecule c-Myc/Max disruptors 
are pursued as potential anti-cancer drugs. Seven small molecules that prevent c-Myc/Max 
association and abrogate c-Myc‟s biological activities have been discovered by Prochownik and 
collaborators [26,27]. These compounds have been shown to bind independently to one of three 
distinct sites on c-Myc, and NMR models of these sites bound to a representative compound 
have been developed [28]. Subsequently, Mustata et al. [29] discovered new c-Myc/Max 
antagonists using a 3D pharmacophore model developed from one parental compound and its 
analogues. Unfortunately, all compounds discovered thus far presented pre-clinical development 
issues, such as toxicity, rapid metabolism and lack of activity in cells. An alternative approach to 
interfere with c-Myc‟s biological activity was demonstrated by Jiang et al. [30], who reported the 
discovery of agonists of Max-Max homodimers using virtual screening and showed that such 
agonists reduced cell proliferation, presumably, by reducing the availability of Max monomers to 
heterodimerize with c-Myc. 
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2.0  CURRENT APPROACHES AND CHALLENGES IN THE DISCOVERY OF 
MODULATORS OF PROTEIN-PROTEIN INTERACTIONS 
This chapter is based on the review “Discovery of modulators of protein-protein interactions: 
current approaches and limitations” by L. Meireles and G. Mustata (Current Topics in Medicinal 
Chemistry, 2011, 11:248-257) [31]. It presents a critical review of the general strategies for 
discovering small-molecule modulators of PPIs, namely: high-throughput screening, fragment-
based drug discovery, peptide-based drug discovery, protein secondary structure mimetics, and 
computer-aided drug discovery. Given the broad scope of the subject, focus is given to the high-
level principles underlying each strategy as well as their advantages and disadvantages. For each 
strategy, at least one example of successful discovery of small-molecule modulator of PPI is 
taken from recent literature. 
2.1 HIGH-THROUGHPUT SCREENING 
High-throughput screening (HTS) technologies enable rapid, automatic screening of hundreds of 
thousands of compounds for therapeutic applications in reasonable timeframes (i.e., weeks). 
Since the late 1980s, continuous technological advances in fields such as instrumentation, 
robotics and assays technologies, as well as methodological advances in the areas of assay 
optimization, control and data analysis have contributed to consolidate HTS as a major drug 
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discovery paradigm [32,33]. However, the success of HTS in delivering starting points for lead 
optimization has not been uniformly distributed among different drug target classes; typically, 
HTS has been more profitable for traditional and well-studied targets (i.e. enzymes and small-
molecule receptors [6]) and less so for PPI targets, where the hit rates have been lower [34,35]. 
One serious limitation of the screening paradigm is that the success or failure of a 
screening campaign is highly dependent on the compatibility of the molecular library with the 
target. HTS will fail to deliver useful lead series if the library screened is chemically and/or 
sterically unsuitable for the target on hands. The fact that HTS is typically more successful when 
applied to traditional targets, as opposed to PPIs in general, may reflect the bias introduced on 
current molecular libraries by past medicinal chemistry efforts. It is now gaining acceptance that 
in HTS compound quantity should not be emphasized over quality. By exploiting prior 
knowledge about the PPI target, such as its structure, known ligands, and moieties known or 
predicted to interact with hotspot areas on the protein-protein interface or allosteric binding sites, 
one may influence the selection of molecules to screen and design PPI-specific molecular 
libraries to increase the chances of identifying useful hits [36]. However, if the target is 
unprecedented and no sufficient information is available to build a focused library, then 
screening a large and chemically diverse library might be more prudent, or another drug 
discovery strategy could be applied. 
HTS is especially useful if the goal is to quickly assess the activity of a large number of 
compounds in cell-based assays. One of the most promising developments in this area is the so-
called high-content screening (HCS) [37], an advanced form of cell-based HTS that exploits 
fluorescence bioimaging technologies to record spatiotemporal data about properties of 
individual cells, and automatic bioimage analysis to translate the information embedded on cell 
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images into phenotypes and their changes induced by potential drugs. Several HCS assays [38-
40] have been developed aiming at screening for small-molecule modulators of PPIs in living 
cells. Recently, Colas [41] reviewed the repertoire of assay technologies available for both in 
vitro and cell-based screening to discover inhibitors of PPIs, whereas Fletcher and Hamilton [42] 
reviewed several successful cases of PPI inhibitors discovered from screening techniques.  
One example of proven success using HTS is the discovery of two classes of inhibitors of 
the interaction between the tumor suppressor protein p53 and its negative regulator 
MDM2/HDM2 (murine double minute 2 / human double minute 2) [43,44] (Figure 3A). 
 
Figure 3. Inhibitors of p53-MDM2 (HDM2).  MDM2 is shown in surface representation and ligands in sticks. 
(A) p53 α-helix bound to MDM2, PDB:1YCR; (B) Nutlin-2 compound (IC50 = 140 nM), PDB:1RV1; (C) 
benzodiazepinedione derivative (Kd = 80 nM), PDB:1T4E. 
Preventing the interaction between p53 and HDM2 with small organic molecules 
constitutes an attractive strategy for developing anti-cancer drugs [45], since over-expression of 
HDM2 in many cancer cells impairs p53 tumor suppressor function [46]. To identify p53-
MDM2/HDM2 antagonists, researchers at Hoffmann-La Roche [43] screened a diverse library of 
compounds. Then, a series of cis-imidazoline analogs, named Nutlins, was discovered following 
optimization of the lead structures. The most potent compound of this series, Nutlin-3, had IC50 
= 90 nM. Figure 3B shows the complex of an analog, Nutlin-2, with MDM2 (IC50 = 140 nM). 
Another class of p53-MDM2/HDM2 antagonists was discovered by researchers at Johnson & 
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Johnson [44] by employing a miniaturized thermal denaturation assay to screen a library of more 
than 338,000 compounds for binding to HDM2. Out of 1,216 hits selected for further 
characterization, 116 compounds were from a benzodiazepinedione series, which yielded a 
compound with Kd = 80 nM after optimization (Figure 3C). 
2.2 FRAGMENT-BASED DRUG DISCOVERY 
Fragment-based drug discovery (FBDD) is a relatively new drug discovery paradigm that has 
been successfully applied to challenging targets, including PPIs [47-55]. In FBDD, a small 
library of molecular fragments (MW < 250 Da), containing up to a few thousand molecules, is 
first screened for binding activity against a target of interest. Subsequently, binding fragments 
are elaborated onto high-affinity compounds by growing a fragment (i.e. fragment evolution), by 
linking two fragments, or by merging fragments based on a common substructure. 
Since molecular fragments bind with low affinity, often in the millimolar range, sensitive 
biophysical methods are primarily used to detect fragment binding. Nuclear magnetic resonance 
(NMR) spectroscopy, X-ray crystallography (XRC) and surface plasmon resonance (SPR) are 
typical biophysical methods used for screening fragment libraries [56-58]. While SPR has higher 
throughput compared to NMR and XRC, it cannot provide information on specific binding 
modes of molecular fragments, whereas NMR and particularly XRC can reveal such extremely 
useful pieces of information. Other biophysical methods applicable to fragment screening 
include mass spectrometry (MS) and isothermal titration calorimetry (ITC). Biochemical 
functional assays have also been successfully applied [59,60]; however, because fragments are 
low-affinity binders, it is necessary to use high compound concentrations, which may interfere 
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with the biochemical assay and result in high false-positive rates. A more specialized approach to 
fragment screening, called tethering, explores the reversible covalent bond formation, through 
thiol-disulfide exchange, between a cysteine residue near the binding site and disulfide-contained 
fragments [61]. In tethering, the identification of the covalently bound fragments is performed 
using mass spectrometry. 
Screening molecular fragments often results in higher hit rates than conventional HTS 
[51,54]. The chemical space of fragments is orders of magnitude smaller than the chemical space 
of higher molecular-weight compounds, such as drug-like compounds, and therefore the gap 
between the chemical space and what is effectively screened is much smaller for fragments. 
From a different perspective, one may think of the chemical space of drug-like compounds as 
being formed by combinations of small fragments; screening fragments thus avoids the 
combinatorial explosion of higher molecular-weight compounds, probing more chemical space 
with fewer molecules [48,52,54]. This efficient sampling of the chemical space is thought to 
contribute to higher hit rates. 
Also contributing to higher hit rates is the fact that fragments tend to be promiscuous 
binders [48,52,54]. That is, due to their smaller size and lower molecular complexity, fragments 
are more likely to optimally accommodate themselves on different target binding sites without 
causing clashes or making unfavorable interactions [62]. Nevertheless, when the binding 
fragments are combined into larger and high-affinity compounds, their molecular complexity 
increases and so does their specificity. Therefore, fragment promiscuity may not necessarily 
constitute a complication and, on the contrary, it may contribute to higher hit rates [43,49,51]. 
Contrasting to that is the promiscuous inhibitors discovered by Shoichet and co-workers [63] 
which frequently appear as false-positives in HTS campaigns. Those promiscuous inhibitors are 
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uninteresting to drug discovery because they act non-specifically through the formation of large 
molecular aggregates.  
Despite the fact that fragments are low-affinity binders, they often bind with high 
efficiency, with most of their atoms directly engaging in strong interactions with atoms on the 
target binding site [48,52,54]. Ligand efficiency, usually defined as the binding free energy 
normalized by the number of heavy atoms is often used as a metric for prioritizing fragment hits 
for lead development and optimization [64,65]. 
The main challenge of FBDD is to transform fragment hits into leads and drug 
candidates. Knowledge of the fragments‟ binding modes on the protein target allows the hits to 
be optimized using rational, structure-based design of compounds. While structural knowledge 
considerably facilitates fragment growing and optimization, it is possible to optimize fragment 
hits in the absence of structural information; for example, by screening a second-generation 
molecular library consisting of random extensions of the fragment hits. Although a certain 
degree of serendipity is required, this procedure is useful not only to those targets that are elusive 
to structure determination but also to targets whose binding site flexibility is difficult to model 
(see e.g. [13]). 
A successful example of FBDD applied to PPIs is the targeting of anti-apoptotic 
members of the Bcl-2 family, namely Bcl-xL, Bcl-w and Bcl-2 proteins, by researchers at Abbott 
Laboratories [66]. Over-expression of these proteins in many cancer types correlates with 
tumorigenesis and resistance to chemotherapy, presumably by binding and sequestering pro-
apoptotic members of the Bcl-2 family [67,68], such as the BH3 α-helix only proteins, Bad and 
Bid. Abbott carried out a large fragment screening using 2D-NMR to discover fragments that 
bind to the hydrophobic BH3-binding groove of Bcl-xL [69]. Two fragment hits, 1 and 2 (Figure 
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4), were identified and shown to bind to distinct but proximal sites [69]. NMR-based structural 
studies guided the linking of the fragments as well as subsequent optimization, which led to 
compound 3 [69]. Compound 3 was then modified to remove binding to human serum albumin 
[70] and also to improve binding to Bcl-2 [71], resulting in compound ABT-737, with high 
affinity (Kd < 1 nM) to Bcl-xL, Bcl-2 and Bcl-w proteins. Finally, compound ABT-263, an 
analog of ABT-737, was designed to improve oral bioavailability [72]. ABT-263 is currently 
undergoing phase II clinical trials for the treatment of small-cell lung cancer, and other 
malignancies [73]. Figure 5 illustrates the crystal complex structure of ABT-737 with Bcl-xL. 
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Figure 4. From fragments hits to clinical trial candidate ABT-263, antagonist of Bcl-xL, Bcl-2 and Bcl-w 
proteins.  
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Figure 5. Crystal structure of Bcl-xL (surface) in complex with ABT-737 (sticks), PDB: 2YXJ. 
2.3 PEPTIDE-BASED DRUG DISCOVERY 
Peptides are powerful tools in drug discovery serving several roles, including their use as probes 
in target validation and chemical genetics studies, as surrogate ligands in HTS competitive 
binding assays, and as intermediate leads for developing non-peptidic small molecule drugs [74]. 
Furthermore, peptides themselves have been developed into therapeutic agents [75,76]. All these 
applications are facilitated by the availability of well-established in vitro protein evolution 
technologies that can discover and optimize peptides for virtually any protein target [77-79]. 
These technologies rely on principles of diversification, selection and amplification to mimic 
nature‟s evolution in vitro and optimize peptides for binding to a target. Among these 
technologies, phage display has been the most commonly used to optimize peptides [77-80]. 
The directed evolution of peptides toward targeting protein-protein interfaces often 
delivers peptides that mimic the binding epitopes of one of the protein partners, albeit using 
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much less scaffold [81,82]. In some cases, it delivers peptides bearing novel binding epitopes 
that are unexpected from the analysis of the protein structure, and/or peptides with higher 
binding affinities than the target‟s natural binding partner. The task of targeting PPIs with 
peptides is considerably facilitated by the availability of in vitro protein evolution methods. 
Perhaps contributing to that is the ability of peptides to assume extended conformations that 
better match the typically large protein-protein interfaces [82]. 
While peptides can be made to target proteins with high specificity and affinity, they 
have generally poor pharmacokinetics properties, such as metabolic instability, low oral 
bioavailability and low cell membrane penetration. These properties present considerable 
obstacles to their widespread use as therapeutic agents. In order to overcome these limitations, 
several peptidomimetic strategies have been developed. The general approach is to introduce 
chemical modifications to the peptide so as to reduce its peptidic character [83-85] and improve 
its metabolic stability and delivery [86-88]. Despite recent progress in this direction, the 
evolution of a peptide lead into a peptide drug remains a challenging problem. Nevertheless, 
peptides are still useful as intermediate leads on which to base the design of non-peptidic small-
molecule compounds that mimic the essential binding features of the peptide. 
The following example illustrates the use of a peptide lead to develop small-molecule 
antagonists of PPIs. The second mitochondria-derived activator of caspases (SMAC) is an 
endogenous pro-apoptotic protein that antagonizes several IAP (inhibitor of apoptosis) proteins, 
including XIAP (X-linked IAP), cIAP-1 and cIAP-2 [89]. SMAC promotes programmed cell 
death by binding its N-terminal tetrapeptide motif Ala-Val-Pro-Ile to IAP proteins [90,91], 
thereby preventing IAPs from inactivating caspases [92], which are required for apoptosis. 
Therefore, SMAC mimetic compounds have the potential to serve as anti-cancer drugs in cancer 
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cells that evade apoptosis by over-expressing IAPs and under-expressing SMAC. Figure 6 shows 
a few SMAC-mimetic XIAP antagonists  that have been designed[93,94] based on the structure 
of the peptide motif AVPI bound to the BIR3 domain of XIAP (Figure 7A). The structure of 
compounds 7-8 modeled on top of the peptide shows that the essential binding features of the 
peptide are retained by the compounds (Figure 7B-C) [94]. Recently, a SMAC mimetic 
compound named AT-406 [95] (Ascenta Therapeutics; chemical structure not disclosed) has 
entered Phase I clinical trials for the treatment of advanced solid tumors and lymphomas. 
 
Figure 6. SMAC mimetic compounds and their binding affinity to XIAP. Compound 4 is the tetrapeptide 
AVPI. 
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Figure 7. XIAP antagonists. (A) the tetrapeptide AVPI bound to the BIR3 domain of XIAP, PDB:1G73; (B) 
and (C) Compounds 7 and 8, respectively modeled on top of the peptide, mimic the binding features of the 
peptide. 
Similarly to the previous example, many PPIs in signal transduction pathways occur via a 
short peptide sequence, about 4-8 amino acids long, known as linear peptides. In signal 
transduction, linear peptides are often recognized by modular or adaptor domains such as the 
members of the following families: PDZ, SH2, SH3, PTB and WW. PPIs mediated by linear 
peptides are natural candidates for peptide-based drug discovery, since the linear peptide by itself 
can act as an antagonist lead, by competing with its parental protein for the same binding partner 
and serving as a starting point for medicinal chemistry. Selective peptide modulators of PPIs in 
intracellular signaling are not only useful probes to decoding the function of interacting proteins 
in signaling cascades, but they are also potential leads for developing non-peptidic drugs 
targeting those interactions [96]. In particular, members of the PDZ and the SH2 domain families 
have been pursued as therapeutic drug targets and several peptidic and non-peptidic small 
molecules have been discovered to prevent protein-protein associations mediated by these two 
domains [97,98]. 
An interesting example of peptides designed to target an extracellular PPI is 
demonstrated by a series of studies that attempted to reproduce with a short peptide the agonist 
activity that 166-residue hematopoietic growth hormone, erythropoietin (Epo), induces on to its 
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receptor, Epo-R. Binding of Epo activates Epo-R via reorientation of two monomeric chains of 
Epo-R, thereby activating two Janus kinases 2 (JAK2) in the intracellular region of Epo-R [99]. 
In turn, the kinases initiate a cascade of events that lead to red blood cell proliferation. Using a 
random phage display peptide library, Wrighton and colleagues [100,101] discovered a 20-
residue cyclic peptide that activated Epo-R, although with less efficiency than the natural ligand 
Epo. The same group was subsequently able to reduce the peptide to 13 residues, while keeping 
its agonist activity, via a series of truncated peptides and mutational studies [102]. However, one 
of the peptide analogs was later found to be an antagonist of Epo-R function [103]. Interestingly, 
other examples of structurally related agonist and antagonists of peptide receptors can be found 
in the literature [104]. Analysis of the crystal structures of the extracellular binding domains of 
Epo-R in complex with each of the two peptides (agonist and antagonist) revealed that the 
peptides induced different domain orientations [103]. This demonstrates that it is not sufficient to 
target the receptor binding site of a natural agonist (i.e., Epo) for eliciting agonist activity, but the 
molecule must also be able to induce specific conformational changes [103,105]. A potent 
peptide Epo-R agonist, called Hematide
TM
 (Affymax, Palo Alto, CA), is currently in Phase III 
clinical trials for the treatment of anemia associated with chronic renal failure [106]. 
2.4 PROTEIN SECONDARY STRUCTURE MIMETIC SCAFFOLDS 
α-helices, β-sheets, and β-turns are basic structural elements of proteins frequently involved in 
mediating protein interactions. The development of small-molecule scaffolds displaying side-
chain functionalities with similar spatial arrangement as those presented by protein secondary 
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structure elements has great potential to deliver compounds that mimic protein-protein 
recognition sites. The basic assumption is that pre-organization of interacting side-chains 
presented by semi-rigid scaffolds enhances the binding affinity of the ligand [107]. In the 
following, we review recent efforts toward the development of α-helix mimetic scaffolds. For a 
detailed review of protein secondary structure mimetic scaffolds, including β-strand and β-turn 
mimetic scaffolds, see Marshall et al. [107] and Hershberger et al. [108]. 
Many protein interactions involve the projection of amino acid side-chains from an α-
helix of one protein toward small pockets on the surface of another protein. This mode of 
interaction is often observed, for example, in intrinsically disordered domains which undergo 
disorder to helix transition upon binding. Such helices are usually amphiphilic α-helices with 
hydrophobic residues lying in one face of the helix at amino acid positions i, i+4 and i+7, 
approximately, facing the binding site, and hydrophilic residues on the other face of the helix, 
exposed to solvent. Because this is a recurring pattern encountered in many protein interactions, 
several research groups have recently attempted to design small-molecule scaffolds whose side-
chains are presented with similar distance and angular constraints as the side-chains i, i+4 and 
i+7 of an ideal α-helix (see Figure 8A). 
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Figure 8. α-helix mimetic scaffolds mimic the presentation of side-chains from one face of an α-helix. (A) 
terphenyl scaffold superimposed on an ideal α-helix; (B) terphenyl scaffold [109]; (C) tripyridylamide 
scaffold [110]; (D) terephthalamide scaffold [111]; (E) tri-substituted imidazole scaffold [112]; (F) Boger et al. 
scaffold [113]. 
Hamilton and co-workers [109] first proposed a tri-substituted terphenyl scaffold to 
mimic the presentation of side-chains from one face of an α-helix (Figure 8A-B). The scaffold 
was applied to mimic the α-helix of the smooth muscle myosin light chain kinase (smMLCK) 
which binds calmodulin (CaM). Three side-chains of this α-helix bind to CaM: Trp800, Thr803, 
and Val807. By attaching analogs of these side-chains (respectively, 1-naphthyl, ethyl and 
isopropyl) into the terphenyl scaffold, a potent small-molecule antagonist of the smMLCk-CaM 
interaction (IC50 9 nM) was designed. Subsequently, Hamilton and co-workers [114] applied the 
same terphenyl scaffold to antagonize the interaction between Bcl-xL and the pro-apoptotic 
proteins Bak and Bad. In this case, the helical BH3 binding domain of Bak served as the 
template for designing several Bcl-xL inhibitors, of which the most potent had Kd value of 
114nM. 
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One problem with the terphenyl scaffold is that it is highly hydrophobic and thus poorly 
soluble in water. This problem was ameliorated with the introduction of a similar but more 
hydrophilic scaffold based on an oligoamide foldamer (tripyridylamide) [110] (Figure 8C). This 
scaffold has the additional advantage of pre-orienting the side-chains through the formation of 
intra-molecular hydrogen bonds. A significant improvement in water solubility was later 
accomplished with a new proposal, the terephthalamide scaffold [111] (Figure 8D), which 
significantly simplified the terphenyl scaffold by replacing the flanking phenyl rings with 
carboxamide groups. The terephthalamide helix mimetic scaffold was also applied to disrupt the 
interaction between Bcl-xL and Bak, delivering several compounds with dissociation constants in 
the low micromolar range [111]. Dömling and co-workers [112] proposed an alternative  α-helix 
mimetic scaffold based on a tri-substituted imidazole backbone (Figure 8E) accessible by 
multicomponent reaction chemistry. Several derivatives of this scaffold showed micromolar 
potency toward inhibiting the interaction between Bcl-w and Bak. More recently, Boger and co-
workers [113] synthesized a library of 8,000 helix mimetic compounds based on the scaffold 
shown in Figure 8F. The library was screened for antagonists of the MDM2-p53 interaction and 
a compound that mimicked the p53 α-helix was identified. 
2.5 COMPUTER-AIDED DRUG DISCOVERY 
Drug discovery is a time-consuming, multibillion dollar endeavor with high risks involved. In 
order to improve productivity in drug discovery and reduce research costs, computational 
methods are indispensable. This section discusses the two typical scenarios in which computer-
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aided drug design can significantly accelerate drug discovery. These scenarios are structure-
based drug design and ligand-based drug design. 
2.5.1 Structure-based drug design 
Structure-based drug design (SBDD) relies on the availability of one or more experimentally 
determined protein structure to generate hypotheses about suitable small-molecule ligands [115-
117]. However, the experimental determination of the target protein structure, a pre-requisite for 
SBDD, is not a trivial task. For some targets, such as membrane proteins and intrinsically 
disordered proteins, structural determination may be very difficult to achieve. 
Virtual screening is the most prominent example of SBDD where the goal is to rank-
order compounds according to their shape and chemical complementarities to the target‟s 
binding site. Virtual screening involves docking and scoring. Docking is the computational 
method for searching the space of ligand poses on the binding site. Scoring associates a weight to 
each pose as a measure of its fit. Several scoring functions have been developed; however, they 
generally suffer from inaccurate treatment of solvation and entropic effects. Nevertheless, virtual 
screening methods continue to improve and have already demonstrated practical utility in many 
drug discovery campaigns. A successful example of virtual screening for PPIs is the 
identification of stabilizers of the Max homodimer, an indirect way of interfering with the 
formation of the c-Myc/Max heterodimer [30]. 
De novo design of ligands is another example of the SBDD approach whereby a ligand is 
built “from scratch” within the target binding site. The main drawback of this approach is the 
lack of synthetic feasibility of the resulting compounds. One of the major challenges of structure-
based approaches has been the modeling of protein flexibility. Structure-based methods are 
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currently unable to accurately predict the binding modes of ligands to proteins that undergo large 
structural rearrangements upon ligand binding [118], a fact that limits the applicability of 
structure-based methods. Recent advances in modeling large conformational changes of proteins 
observed upon binding have been made recently using Elastic Network Models. We will revisit 
this topic in Chapter 3.0 . 
2.5.2 Ligand-based drug design 
Ligand-based drug design (LBDD) exploits the information about known active 
compounds (and possibly inactive compounds as well) to discover new actives [119]. Ligand-
based approaches rely on the central similarity-property principle, which states that similar 
molecules should exhibit similar properties [120]. Hence, the activity prediction of a compound 
or a set of compounds is made based on the similarity or distance to a set of reference ligands 
with known bioactivity to a protein target [121]. Different types of two- and three-dimensional 
molecular descriptors and substructures in combination with a variety of classification schemes, 
such as decision trees, Bayesian statistics, neural networks or other machine-learning methods 
have been used for this purpose. 
Pharmacophore-based virtual screening can be considered to be at the intersection 
between structure-based and ligand-based approaches, as either the protein structure or known 
ligands can be used as references to build the models (respectively referred to as, receptor-based 
pharmacophore and ligand-based pharmacophore). One advantage of similarity searching over 
pharmacophore-based search is that it does not require a set of structurally unrelated compounds 
of similar biological activity to derive a model. When using similarity searching, even one active 
molecule can be used to search a database for related compounds. This similarity-based virtual 
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screening has proven very convenient, as it is computationally inexpensive and requires little 
information [122]. It mostly uses 2D descriptors, also called topological descriptors, which are 
derived from the connectivity table of the molecule and take into account distances among atoms 
in terms of number of bonds in the shortest path between them. The most commonly used 
descriptors are topological fingerprints [123], which encode the presence or absence of 
substructural fragments in molecules in a binary fingerprint, without taking into account the 
number of occurrences of the feature. These fingerprints can be pre-calculated and compared, 
usually by means of Tanimoto distance, in a very fast and efficient manner to any reference set. 
In terms of the novelty of the leads discovered, however, pharmacophore search provides more 
scaffold hopping capability than fingerprint-based methods. 
One example of a ligand-based pharmacophore modeling for PPIs is the development of 
a 3-dimensional pharmacophore model using a set of known inhibitors of c-Myc/Max 
heterodimer formation [29]. This was the first report of a pharmacophore model to provide a 
hypothetical picture of the main chemical features responsible for the activity of c-Myc/Max 
heterodimer disruptors. The model successfully identified a set of structurally diverse 
compounds that showed affinities in the µM range and growth inhibitory activity against c-Myc-
overexpressing cells [29]. 
2.6 FINAL REMARKS 
Unfortunately, there is no single best drug discovery paradigm capable of tackling all drug 
targets. It is thus important to understand the strengths and weaknesses of each approach, and 
realize that, in fact, they are complementary approaches. The synergism created by combining 
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approaches, e.g., combining experimental with computational approaches in particular, may be 
the key to increase productivity in this field. New classes of drug targets require new ways of 
thinking, and as scientists experience the transition from enzymes and small-molecule receptors 
to PPI targets the field will further develop in the coming years. 
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3.0  MODELING PROTEIN FLEXIBILITY COUPLED TO LIGAND BINDING 
USING ELASTIC NETWORK MODELS 
This chapter is based on the review “Pre-existing soft modes of motion uniquely defined by 
native contact topology facilitate ligand binding to proteins” by L. Meireles, M. Gur, A. Bakan 
and I. Bahar (in press in Protein Science) [124]. 
Modeling protein flexibility is a challenge task owing to the enormous size and 
complexity of proteins‟ conformational space - which preclude exhaustive sampling - and the 
prohibitively large computational times required to perform fully atomistic molecular dynamics 
simulations up to the timescales of biological significance. Moreover, the complexity of the 
problem is compounded by inaccuracies of scoring functions and force fields. 
When dealing with complex problems, robust simplifications hold great promise. Along 
those lines, coarse-grained normal mode analyses (NMAs) have been used to model large-scale 
collective motions of proteins. In particular the NMA of unbound proteins using Elastic Network 
Models (ENMs) proved to predict soft modes of reconfiguration in accord with conformational 
changes experimentally observed upon ligand binding [125,126], implying that proteins‟ intrinsic 
dynamics plays a major role in defining the bound conformations. We present here a summary of 
the foundations of ENMs-based NMA for modeling the collective motions of proteins, and 
several recent applications showing how they have been effectively adopted for modeling the 
conformational changes of proteins observed upon ligand binding. Most importantly, these 
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studies help improve our understanding of the molecular basis of observed recognition and 
binding events, and stipulate the importance of the energy landscape, or the soft paths/modes of 
motion away from the native state energy minimum which predominantly define the bound 
conformers being selected. 
3.1 PROTEIN FLEXIBILITY IN MOLECULAR RECOGNITION AND BINDING 
Several molecular recognition models have been proposed with different perspectives for the role 
of protein flexibility in molecular recognition and binding. Fischer‟s lock-and-key model [127] 
postulates that enzymes and their substrates are rigid, complementary-shaped bodies that fit each 
other as a lock and key. Although the importance of shape (and chemical) complementarity to 
binding is widely acknowledged nowadays, the lock-and-key model neglects protein flexibility 
by treating proteins as rigid molecules. Since this model has been proposed (more than a century 
ago), advances in experimental technologies have improved our understanding about proteins, 
and it is now clear that protein flexibility varies over a spectrum ranging from fairly rigid 
globular proteins to intrinsically disordered proteins - characterized by the absence of stable 
secondary structures. Most proteins, however, are comprised of combinations of rigid (e.g., 
hydrophobic core) and flexible substructures (e.g., loops and hinge residues), evolved to 
collectively confer the protein the dynamics required to perform its function. 
To explain the structural changes of proteins observed upon ligand binding, Koshland 
proposed the induced-fit model [128], whereby the ligand drives the conformational changes of 
the protein structure to optimize protein-ligand interactions (Figure 9A). Contrasting to this view, 
the conformational selection model proposed by Monod, Wyman, and Changeux (MWC model) 
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[129] postulates that (a) an ensemble of protein conformations pre-exists in dynamical 
equilibrium prior to ligand binding; and (b) the ligand binds to, and stabilizes, one such 
conformation, shifting the equilibrium towards the bound state (Figure 9B) – see Boehr et al. 
[130] for a review of recent experimental evidence in support of conformational selection. 
 
Figure 9. Schematic diagram of models for ligand binding. The protein is shown in white/gray, and the ligand in 
red. (A) Induced-fit; (B) Conformational selection; (C) Conformational selection followed by induced-fit. See text 
for details. In parts B and C the protein is originally in dynamic equilibrium with an ensemble of fluctuating 
conformers (boxes at the left), represented here by two conformers for simplicity. 
Despite fundamental differences between the induced-fit and conformational selection 
models, it is likely that both mechanisms may co-occur in binding: conformational selection 
might play a dominant role in defining the global/large conformational changes (intrinsic to the 
protein) that are exploited for ligand binding, especially at the early stage of binding; and 
induced-fit would play a role in inducing local and ligand-specific changes in the vicinity of the 
ligand, such as side-chain flips and loop rearrangements, so as to further optimize the  
interactions (Figure 9C). 
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3.2 ELASTIC NETWORK MODELS: THEORY AND METHODS 
Elastic Network Models (ENMs) have been widely used in recent years for investigating the 
cooperative motions that biomolecular systems tend to undergo under equilibrium conditions. 
The basic assumption in ENMs is that the dynamics of a protein is uniquely defined by its 
contact topology, represented as a network of nodes and springs. 
ENMs were originally inspired by the work of Tirion [131], who demonstrated that the 
global modes obtained by Normal Mode Analysis (NMA) with a detailed force field are almost 
identically reproduced by adopting a single-parameter harmonic potential between all atom-pairs 
within a short interaction range (≈ 5.0 Å). Several studies have confirmed since then that the 
global modes of biomolecules are robustly defined by the overall shape, or inter-residue contact 
distribution, irrespective of the detailed structure and energetic [126,131-135]. Most importantly, 
these modes have been shown in many studies to be relevant to functional motions, hence the 
significance of identifying them by computational methods. 
Two most widely used ENMs are the Gaussian Network Model (GNM) [136,137] and the 
Anisotropic Network Model (ANM) [138-140], where the node positions are identified by the 
coordinates of -carbons known from experiments, and all residue pairs whose -carbons are 
located within a cutoff distance rc are connected by a spring of uniform force constant . The 
respective underlying potentials in these two models are: 
Equation 1 
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in accord with the statistical mechanical theory of polymer networks[141], and 
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Equation 2 
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0 
and Rij
 
are the equilibrium and instantaneous distance vectors between residues i and j, 
0
ijR and ijR  are their magnitudes, and ij is the ij
th
 element of the Kirchhoff matrix, the off-
diagonal elements of which are defined as ij = -1 if 
0
ijR  < rc and zero otherwise, and the diagonal 
elements are evaluated from the summation ii = -∑j ij over all off-diagonal elements in the i
th
 
row (or column). As such, the GNM potential includes contributions from both distance and 
orientation changes, whereas the ANM potential is exclusively based on distance changes. 
A coarse-grained (single-node-per-residue) harmonic potential for all residue pairs was 
first proposed by Hinsen [142,143], the difference from the ANM being the adoption of a 
distance-dependent force constant (thereby eliminating the parameter rc). Using a uniform force 
constant for each pair of residues within a given cutoff treats both strong/specific (covalent 
bonds between consecutive residues or hydrogen bonds within helices and sheets) and 
weak/nonspecific (hydrophobic contacts between side-chains) interactions identically. Variations 
of ANM using more elaborate force constants have been shown to slightly improve the accuracy 
of predictions [144,145]. Examples include force constants weighted by an exponential decay 
function [142], negative exponents [144,146], and another form combining negative exponent 
and contact area between residues [147]. Recently, using an entropy maximization method, 
Lezon and Bahar [148] further investigated the determinants of structural dynamics. To this aim, 
they optimized the GNM force constants based on the covariance matrices derived from NMR 
ensembles. Their study suggests that the next level of refinement in ENMs could be to 
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incorporate secondary structure-dependent force constants, i.e. stiffer springs for residues 
forming hydrogen bonds in a helix or a sheet. 
The spectrum of ANM normal modes is obtained by NMA using the potential VANM 
(Equation 2), which is simply found by eigenvalue decomposition of the Hessian H, the matrix 
of the second derivatives of VANM with respect to residue position. The eigenvalue decomposition 
of Η  yields 3N-6 non-zero eigenvalues and corresponding eigenvectors. The k
th
 eigenvector, uk 
= (ux1 uy1 uz1 … uzN)k
T 
describes the normalized displacements of the N residues in the x-, y- and 
z- directions as driven by 
 
mode k, and the corresponding eigenvalue, k, provides a measure of 
the frequency (squared) of that mode, or the statistical weight (equal to 1/k) of square-
displacement along this mode. The change R|k  in the configuration R
0 
= [x1
0
  y1
0
  z1
0
  x2
0
   … 
zN
0
]
T  
caused by the fluctuation along ANM mode k is conveniently expressed as [149]: 
Equation 3 
R|k = ± s (kBT/k)
½
 uk 
where ±s is a variable uniformly scaling the size of the fluctuation along mode k, T is the 
absolute temperature, and kB is the Boltzmann constant. 
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3.3 COMPARISON OF COMPUTATIONAL PREDICTIONS WITH THE 
PRINCIPAL MODES OF BINDING OBSERVED IN EXPERIMENTS 
3.3.1 Metrics for comparison 
When two structures (A and B) are available for a given protein, a metric of structural change is 
the 3N-dimensional deformation vector d = RA – RB obtained from the difference between the 
coordinates of all -carbons after optimal superimposition of the structures to eliminate rigid-
body translational and rotational differences. The correlation cosine between d and ANM mode 
uk provides a measure of the level of agreement between experiments and theory. Of interest is 
the correlation with soft/low-frequency modes (e.g., k = 1-3) to assess whether the 
experimentally observed (usually functional) changes concur with the „easiest‟ reconfigurations 
the structure intrinsically tends to undergo. As discussed in Section 3.3.2, this has been the case 
in many applications, suggesting that structures have evolved to favor soft modes that are being 
exploited during functional changes in conformation. 
Previous work has shown that structural ensembles can be advantageously analyzed to 
extract the principal modes of structural variations, which, in turn, may be compared to ANM 
soft modes [125]. This is achieved by a principal component analysis (PCA) of the 3Nx3N 
covariance matrix, C, constructed for the ensemble of structures (e.g., m of them, where m ≤ 3N 
usually) resolved for the studied protein, after optimal iterative superposition of these structures 
[125]. Eigenvalue decomposition of C as 
1
m
ii


C pi pi
T
, yields the principal components pi 
(eigenvectors) and corresponding eigenvalues i.  1 corresponds to the largest variance and p1 
describes the most dominant structural change. The fractional contribution of mode pi to 
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experimentally observed heterogeneity/variance of structures is i /kk where the summation is 
performed over all PCA modes. The top three modes usually account for more than 50% of the 
heterogeneity observed in X-ray crystallographic structures. They also tend to be highly 
collective in terms of the distribution of the motion among the residues, although in some cases, 
they may only describe localized (e.g. loop) motions. 
The overlap between the k
th
 ANM mode and the i
th
 PCA mode is given by the correlation 
cosine Oik = pi. uk [140]. The cumulative overlap is used to measure how well a subset of low 
frequency ANM modes (e.g. J of them) predicts a PCA mode i and is defined as [150]: 
Equation 4 
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Note that COi
J
 = 1 for J = 3N-6, i.e., the 3N-6 ANM eigenvectors form a complete set of 
orthonormal basis vectors. 
3.3.2 Comparison of anisotropic network model soft modes with the structural changes 
experimentally observed between bound and unbound forms 
Several studies support the predictive capacity of ENMs and provide a basis for their application 
to modeling the conformational changes of proteins associated with complex formation. For 
example, Tobi and Bahar [151] showed for protein-protein complexes with known structures in 
the apo and holo forms (LIR-1/HLA-A2, Actin/DNase I, Cdk2/cyclin and Cdk6/p16
INK4a
) that 
there is a good agreement between the experimentally observed structural changes (between apo 
and holo forms) and the collective motions predicted by the ANM for the apo structure. For each 
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case, a single low-frequency ANM mode could be identified with high correlation with the 
experimentally observed principal structural change p1 (also designated as PC1). Similar results 
for antigen-antibody complexes were reported by Keskin [152]. Bakan and Bahar [125] further 
showed that the good agreement was not restricted to PPIs, but protein-small molecule 
interactions as well, as exemplified by three enzymes (HIV-1 reverse transcriptase (RT), p38 
MAP kinase, and Cdk2) for which sufficiently large ensembles of structures in liganded and 
unliganded forms were available. Notably, similar results were obtained [125] for sufficiently 
broad ensembles of structures resolved by NMR (residual dipolar coupling measurements) and 
proteins such as ubiquitin [153] and calmodulin [154]. Figure 10 illustrates the close 
correspondence between the experimental conformational space and the ANM predictions for the 
aforementioned enzymes and for calmodulin. Correlations in the range 0.84 - 0.99 are observed. 
In a similar study involving HIV-1 protease, Yang et al. [150] reported close similarity between 
the motions predicted by ENMs and those calculated by PCA of a large set of X-ray structures, 
PCA of NMR ensemble, and PCA of MD simulation snapshots (a.k.a. essential dynamics 
analysis). 
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Figure 10. Comparison of principal changes in structure observed in experiments and predicted by the ANM. 
Results are displayed for (A) HIV-1 RT, (B) p38 MAP kinase (p38), (C) Cdk2, and (D) calmodulin (CaM) 
complexed with myosin light chain kinase (MLCK) datasets. Experimental datasets (113 HIV- RT X-ray structures, 
74 p38 structures, 106 Cdk2 structures, and 160 CaM-MLCK NMR models) were subjected to PCA to obtain the 
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dominant changes in structures, PC1, in each case. A representative structure from each set was analyzed by ANM 
to determine the global modes ANM1-ANM3. The ribbon diagrams (left) illustrate the global movements predicted 
by theory (green arrows) and exhibited by experiments (violet arrows). The plots on the right display the dispersion 
of the examined models/structures along these top-ranking mode axes derived from experiments (PC1) and theory 
(ANM 1, 2 or 3). A bound inhibitor colored gray is shown for HIV-RT, p38, and Cdk2 to highlight the binding 
pocket. The colored dots in the right plots refer to different types of structures, as labeled. Projected values, in Å, 
represent a collective distance/deviation for the entire structure. See Bakan and Bakar for details [125]. Results, 
diagrams and plots were generated using ProDy [155]. Credit: the analysis and figure are attributed to Ahmet 
Bakan. 
3.4 ENM-BASED MODELING OF PROTEIN FLEXIBILITY AND STRUCTURAL 
CHANGES INVOLVED IN INHIBITOR BINDING 
The previous section underscores the close overlap of the low-frequency modes of motions 
predicted by the ANM with the principal structural changes observed experimentally upon ligand 
binding. Here, we describe how theoretically predicted normal modes have been applied to 
modeling protein flexibility coupled to binding. Among these, two application patterns stand out: 
generating conformational ensembles for docking, and simultaneously docking the ligand and 
deforming the protein. 
3.4.1 Generating conformational ensembles for docking 
A practical approach to improving molecular docking is using an ensemble of conformations 
obtained by experimental or computational means [156]. Conformations can be generated using 
a number of web servers including ANM [157], ElNémo [158], FlexServ [159], Fiberdock [160], 
or using software packages like ProDy [155].While the number of modes to use for sampling or 
the relevance of the modes to the specific binding problem varies, the general recipe is to use a 
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small subset (up to 8-10) of soft modes, assuming that these will effectively map the most 
significant changes in structure. An alternative approach is to select the modes that are expected 
to facilitate ligand binding, e.g., those accompanied by local conformational changes at the 
binding site [161], or those accommodating the specific force applied by the ligand [162].  
One of the earlier studies that took advantage of normal modes for generating alternative 
conformers to be then used in docking simulations is the work of Cavasotto, Kovacs and 
Abagyan [161]. The authors proposed a scoring mechanism for selection of ENM modes that are 
most relevant to the area of interest (e.g., binding site) by assessing the contribution of each 
mode to the deformability of that area. A scoring algorithm was applied to identifying a few 
modes, within the mid-frequency range, that best describe the loop flexibility in the binding 
pocket of cAMP-dependent protein kinase. To generate deformation vectors, these relevant 
modes were linearly combined by exhaustively sampling all combinations of uniformly 
discretized linear coefficients. After correcting unphysical geometries with energy minimization, 
the side-chains were optimized by docking known binders using a flexible side-chain docking 
algorithm. While this study demonstrated the utility of normal modes, it also raised concerns 
about the choice of normal modes, i.e., whether one needs to examine higher modes for accurate 
binding of ligands. The above calculations demonstrate however that inclusion of up to 20 modes 
usually provides a good description of structural changes associated with ligand binding. Further 
refinements (e.g., side chain isomerizations) would require energy minimizations or MD 
simulations with detailed potentials. In a more recent study from the same laboratory, Abagyan 
and coworkers [163] showed for a benchmark set of 28 bound structures that a consistent 
improvement in cross-docking results is achieved (compared to docking simulations with single 
experimental receptor conformation) when binding site ensembles generated with ENMs were 
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used. Likewise, Perahia and coworkers have made use of NMA to predict the binding modes of 
inhibitors in the active sites of matrix metalloproteinases (MMPs) correctly [164]. 
A more recent example is the work of Sperandio et al. [165] who explored the 
conformational space accessible to Cdk2 by deforming the structure along the first 25 lowest-
frequency modes obtained from all-atom NMA (note that the lowest frequency modes are highly 
robust and reproducible with either full atomic or ENM-based models). For each mode, two 
deformations were generated in each direction, up to a mass-weighted RMSD of 2 Å. Thus a 
total of 50 deformed structures were generated. Unphysical geometries created by deforming the 
structure along each mode were eliminated by energy minimization. Since energy minimization 
may introduce artifacts, significantly altered conformations were discarded. The remaining 
conformations were then used to dock inhibitors of Cdk2, resulting in improved accuracy 
compared to the docking of the inhibitors onto an energy- minimized apo structure. 
3.4.2 Coupled docking and deformation along normal modes 
Current docking software handles a limited number of conformers, and hence limits the 
researcher to a small number of normal modes when generating ensembles. This has the potential 
shortcoming for highly flexible binding sites, as even for a small number of modes, let‟s say 6, 
the number of potential combination of these modes is 2
6
 = 64; and more importantly, the size of 
motion along a given mode usually varies depending on the ligand, as shown in recent 
examination of bound structures [125]. A computationally manageable approach would be to 
sample conformers at short intervals (e.g., total of 20 conformers, 10 in each direction, positive 
and negative), along each individual mode, but this approach has the potential problem of 
missing relevant conformations resulting from the combinations of modes. The alternate 
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approach is in situ utilization of normal modes, i.e., guiding protein energy minimization by 
normal modes during docking. As this approach can handle larger number of modes, it promises 
generating conformers specific to the ligand of interest. 
Zacharias and Sklenar [166] proposed to use the deformation along the soft modes as 
variables in an energy minimization procedure that aimed at optimizing the steric 
complementarity of the receptor protein with a pre-docked ligand. The energy function consisted 
of an intermolecular interaction term and a receptor deformation penalty. Each mode contributed 
to the deformation penalty a quantity proportional to the fourth power of the magnitude of the 
deformation along that mode. The square of the eigenvalues was taken as force constants to 
account for the relative stiffness of the modes. The receptor deformation penalty thus calculated 
avoided the computationally more demanding calculation of the receptor intramolecular energy 
at each minimization step. The method was first applied to a DNA-ligand complex using the 
softest 40 modes calculated from all-atom NMA of the unbound DNA structure. The ligand was 
kept fixed in the known binding site, and the unbound DNA structure was deformed by energy 
minimization along the normal modes, resulting in a DNA structure with improved shape 
complementarity with respect to the ligand and more similar to the bound DNA structure. 
Subsequently, the method was applied to flexible protein-ligand docking using the soft modes 
derived from PCA of MD trajectories [167]. More recently, May and Zacharias used ENMs in 
place of all-atom models in NMA, and included the translational and rotational degrees of 
freedom of the ligand in the minimization scheme along the soft modes of the receptor structure 
[168,169]. Finally, side-chain flexibility was included at each minimization step with the help of 
a rotamer trial protocol [170]. This latter methodology has been tested [170] for two cases: 
docking known Cdk2 inhibitors to unbound kinase structures, and cross-docking of inhibitors to 
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several bound structures. Figure 11 illustrates the improvement in ligand placement achieved 
with the proposed methodology. 
 
Figure 11. Improved docking of Cdk2 inhibitors by modeling the flexibility of Cdk2. Cdk2 (gray cartoon), 
experimental inhibitor binding mode (green), docked inhibitor binding mode (red). (A) Ligand from PDB 1E9H 
docked to apo structure of Cdk2 (PDB 1HCL) using rigid receptor (left) and flexible receptor modeling (right). (B) 
Cross-docking of inhibitor from PDB 1FVV to another inhibitor bound structure of Cdk2 (PDB 1E1V) using rigid 
receptor (left) and flexible receptor modeling (right). Adapted with permission from May and Zacharias [170] - 
Copyright 2008 American Chemical Society. 
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Lindahl and Delarue [171] have proposed an alternative strategy for refining protein-
ligand and protein-DNA structures: to optimize the deformation along each mode, one at a time, 
by scanning the mode amplitudes and calculating the resulting intermolecular energy. They have 
found that pre-sorting the modes in order of single-mode largest energy reduction achieved better 
results than using them in order of mode frequency (see Figure 12). The modes in this study were 
calculated using all-atom ENM, thus the positions of side-chain atoms were directly obtained, 
with the caveat that the model would not account for rotameric transitions in side-chains. 
 
Figure 12. Refinement of maltodextrin binding protein along low-frequency normal modes. (A) The unbound 
structure (red; PDB 1OMP) is superimposed onto the ligand (yellow) bound structure (blue, PDB 1ANF). The initial 
RMSD is 3.77 Å (B) After refinement of the unbound form along the top 5 lowest frequency (all-atom) ENM 
modes, Lindahl and Delarue [171] obtained a structure with an RMSD of 1.86 Å from the experimentally known 
bound form. Shown is a similar structure (RMSD of 1.51Å) obtained by projecting the deformation vector along the 
two lowest-frequency ANM modes. 
Mashiach, Nussinov and Wolfson [160,162] have proposed a docking refinement 
protocol based on a new strategy for selecting the most relevant normal modes; namely, those 
modes that exhibit the highest correlation with the direction of the repulsive van der Waals 
(vdW) forces the ligand exerts on the protein. Energy minimization along these modes relaxes 
the protein to accommodate the ligand. This strategy allows for iterative selection of relevant 
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normal modes from an unlimited number of a priori modes. The application to 20 protein-
protein complexes demonstrated the utility of the approach for improving the accuracy of docked 
conformers and obtaining the correct ranking of near-native docking solutions [162]. 
3.5 FINAL REMARKS: PRE-EXISTING SOFT MODES OF MOTION FACILITATE 
LIGAND BINDING TO PROTEINS 
An alternative view in addition to the three shown in Figure 9 is suggested by the wealth of 
computational data presented above to be in accord with experimental data. This view, shortly 
termed pre-existing paths, as opposed to pre-existing substates, is based on the shape/curvature 
of the energy landscape near the native state of the protein. It considers the fluctuations near the 
global energy minimum, rather than the jumps between the local minima. The energy surface has 
different curvatures along each of the 3N-6 collective degrees of freedom (or collective 
fluctuation directions) that define various reconfiguration mechanisms (for a structure of N 
sites/nodes).  The intrinsic motions thermally accessible to the protein are simply fluctuations 
along these collective directions, or modes, each of which defines an uphill path of 
reconfiguration away from the native state (bottom of the energy well). A multitude of uphill 
paths are therefore accessible during the collective fluctuations due to the stochasticity of 
thermal motions, those with softer curvature being more probable and larger in amplitude. 
Numerous applications including those summarized here have suggested that these very 
fluctuations along the soft modes are (i) uniquely encoded by the native structure, (ii) robustly 
computed using simple models, such as the ANM exclusively based on native contact topology 
and (iii) functionally relevant, e.g., they enable the opening and closing of the binding site, they 
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trigger allosteric switch mechanisms, and even facilitate the stabilization of catalytically 
competent/pre-disposed states. A ligand in the vicinity of a protein undergoing these fluctuations 
would selectively recognize an instantaneous conformer that provides an optimal binding site, 
and stabilize this transient conformer into a new bound substate. The encounter with the ligand 
might thus change the energy landscape (originally an uphill path) into a stable intermediate state 
(local energy minimum) or equilibrium state (a new global energy minimum), even if that 
particular conformer was not a pre-existing „substate‟, but simply accessible via a pre-existing 
„soft path‟. 
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4.0  LIGAND-BASED DRUG DESIGN: A NEW CLIQUE-BASED APPROACH TO 
BIOACTIVE CONFORMATION IDENTIFICATION 
In this chapter we present a new approach for generating models of the bioactive conformation 
of molecules in the absence of protein structure, the validation and selection of the „best model‟ 
in accord with experimental data, and its use to identify new bioactive compounds. We also 
show the application of the method to known c-Myc/Max inhibitors. 
Pharmacophore-based superposition of bioactive compounds is a popular approach to 
generate plausible models of their bioactive conformations. The underlying assumption is that 
bioactive molecules share a common binding mode to a - possibly unknown - biological target, 
or, in other words, bioactive molecules share a common spatial distribution of compatible 
chemical/pharmacophore features. Pharmacophore-based methods attempt to superimpose the 
bioactive molecules such as to maximize the overlay of common 3D pharmacophore features. 
However, a problem with that approach occurs when the molecules are similar; in this case, 
multiple superpositions are possible, raising doubts about the „correct‟ superposition model to 
use. It is therefore important to generate a list of candidate superposition models and to select the 
one that correlates best with experimental data. 
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4.1 PROBLEM FORMULATION 
The input to the algorithm is a set of M bioactive molecules, with at most C pre-generated 
conformations per molecule. The output is a list of N superposition models. These models are 
then tested for their ability to reproduce known experimental data, such as the ability to 
discriminate between known active and inactive compounds. Finally, the best model is selected 
and used to screen for new active compounds in molecular databases. 
Typically, putative bioactive conformations are identified after optimal superposition of 
the molecules. Our strategy works in the opposite direction: first we identify a set of (putative) 
bioactive conformations, one conformation per molecule, to subsequently generate a 
superposition model. Note that since there may be up to C
M
 possible combinations of 
conformations, it would be impractical to exhaustively evaluate all possible combinations. For 
example, in a typical scenario involving 5 molecules, each with 100 conformations, there would 
be 10
10
 possible ways to select a set of conformations. Most importantly, what would be the 
criterion to label a set of conformations as putative bioactive? 
The answer to the above question paves a way for solving the problem efficiently. Under 
the common binding mode assumption, the bioactive conformations should be mutually similar, 
in terms of both their shape and chemical features. Thus, by finding mutually similar 
conformations, we should, in principle, identify putative bioactive conformations. This insight 
reduces the problem to selecting one conformation for each molecule such as to maximize the 
sum of pairwise similarity scores among the selected conformations. In turn, this can be solved 
efficiently using a maximum-edge weight clique algorithm. 
Let G be a graph in which the vertices represent the individual conformations. An edge 
connects two vertices if, and only if, the corresponding conformations belong to different 
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molecules. The weight associated with each edge is the shape- and chemistry-based similarity 
score between the two conformations. Finding a set of conformations that maximize the sum of 
pairwise similarity scores corresponds to finding a clique of size M with the maximum sum of 
edge weights (see Figure 13). The next section describes the algorithm for finding such a clique. 
 
Figure 13. Reduction of the bioactive conformation identification problem to the maximum edge weight 
clique problem. The vertices in the graph represent conformations. There is an edge connecting two conformations, 
if they are from different molecules (not all edges are shown for simplicity). Finding a set of conformations that 
maximize the sum of pairwise similarity scores corresponds to finding a clique (red color) of size M with the 
maximum sum of edge weights (similarity scores). 
4.2 ALGORITHM 
The maximum edge weight clique problem is a well-known NP-hard problem in computer 
science. Here we describe an integer linear programming (ILP) formulation of the problem 
which was inspired by an ILP formulation of the protein side-chain packing (SCP) problem in 
computational biology [172]. The SCP problem is related to our formulation of the bioactive 
conformation identification problem, as they both are combinatorial optimization problems with 
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objective functions expressed as a sum of pairwise scores (side-chains interaction energy in the 
SCP problem). The realization of this connection is important because techniques applied to one 
problem are transferable to the other. For instance, the Dead End Elimination [173] algorithm, 
which has been successfully applied to the SCP problem, could also be useful to the bioactive 
conformation identification problem. Our decision to use the ILP formulation was motivated by 
the ease of implementation and availability of standard ILP solvers. 
In the ILP formulation, we associate a binary decision variable {0,1} to each vertex and 
edge of the graph. Let xu be the binary variable associated to vertex u, and xuv be the binary 
variable associated to edge (u,v). If vertex/conformation u is selected, then xu=1; otherwise, xu=0. 
If both vertices u and v are selected (xu = 1 and xv = 1), then xuv = 1; otherwise, xuv = 0. With this 
coding scheme, the objective function can be written as                  where wuv is the 
weight of edge (u,v). To ensure that only one conformation per molecule is selected, we add one 
constraint for each molecule j=1,…,M:            . In addition, to ensure the correct 
assignment of edge variables induced by assignments of vertex variables, we add the following 
additional constraints [172]: 
Equation 5 
                     and        
         
 
where            denotes that   is selected from all molecules other than  . This constraint 
demands that if a vertex is not selected (xv = 0), then no adjacent edge can be chosen; if a vertex 
is selected (xv = 1), then exactly 1 adjacent edge is chosen for each vertex/conformation set. This 
ensures the selection of edges that are in the subgraph induced by the choice of conformations. 
The ILP formulation is shown below: 
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Equation 6 
max        
     
            
   
      
                   
                     and        
         
              
 
 
With this formulation, putative bioactive conformations can be found using any ILP 
solver software, such as Gurobi [174], CPLEX [175] and GLPK [176]. In the present study we 
used the software Gurobi 4.0. To find several optimal or near optimal solutions, the ILP problem 
is solved multiple times, at each new iteration the last solution found is excluded by adding the 
constraint [172]:           , where S={ u | xu = 1} is set of conformations selected in the 
previous iteration. This requires that at the next iteration a new solution differs from previous 
solutions by at least one conformation. 
4.2.1 Calculation of the similarity score between two conformations 
Prior to solving the ILP problem, we need to compute the weights wuv of all edges in the graph, 
that is, the similarity score between all pairs of conformations from different bioactive 
molecules. To this end, we use the program ROCS 3.1.2 (OpenEye Scientific Software) for 
shape-based superposition of molecules [177-179]. In ROCS, the shape of a molecule 
corresponds to the volume occupied by its atoms in 3D. To superimpose two molecules based on 
their shapes, ROCS maximizes the intersection volume (overlap) of the two molecules. 
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The most striking feature of ROCS is how it efficiently computes, analytically, volume 
overlaps and their gradients with respect to the (x,y,z) coordinates. This is achieved by using 
Gaussian functions centered at the atoms, in lieu of the hard spheres commonly used to represent 
the vdW volume of atoms [177-179]. The smoothness of the gradients introduced by Gaussian 
functions avoids numerical instabilities in the optimization of the rigid-body transformation that 
maximizes the overlap of the two molecules. Next we briefly review the theory behind the shape-
based superposition of ROCS using Gaussian functions. 
The volume of a hard sphere of radius R is 
 
 
   , which is theoretically calculated from 
the integral: 
Equation 7 
                 
 
 
    
       
         
         
  
where the integral is over the whole space, ri=|r-ri| is the distance from the sphere center   , and 
      is the volume characteristic function. The intersection volume of two hard spheres can be 
computed from their respective characteristic functions, f1 and f2: 
Equation 8 
                      
 
It is clear that the product              equals 1 only where the two spheres overlap and 0 
otherwise; therefore, Equation 8 corresponds to the volume of the overlap of two spheres by 
analogy to Equation 7. Grant and Pickup [177] replaced the step function f(r), characteristics of a 
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hard sphere, by a Gaussian function with two defining parameters: its prefactor p and its width w 
(see Equation 9). They found that the volume of a hard sphere could be recovered to high 
accuracy (~ 0.1%) by fixing p to 2.7 and setting w for each atom such that the volume integral 
agreed with its hard-sphere volume. 
Equation 9 
          
 
 
 
Since the product of two Gaussians is another Gaussian, the intersection volume 
calculated from Equation 8 has a simple analytical solution. Grant and Pickup [177,178] 
provided analytical equations to compute the intersection volume of N Gaussians (      
   ) as well as and the gradient of the intersection volume with respect to the coordinates. 
These equations are written as functions of the parameters of each Gaussian (p, w and the 
coordinate center). The calculation of intersection volumes,          , are used to compute 
the intersection volume of two molecules. First note that the volume of a molecule with two 
atoms is given by 
Equation 10 
                  
and the volume of a molecule with N atoms, i.e., a generalization of the above, is given by: 
Equation 11 
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Note that we need to take into account double, triple, and higher order intersections 
between atoms. Given two molecules A and B, their volumes are computed as in Equation 11 
and the intersection volume as in Equation 12: 
Equation 12 
            
       
          
         
          
         
   
where all the intersection terms up to the sixth order and between atoms within a cutoff distance 
are computed analytically. 
Four starting points for optimization are generated by aligning the molecules‟ centroids 
and their two largest principal components (each pair of principal components can be aligned in 
two directions). ROCS then performs a gradient-based maximization of the volume overlap 
using a quaternion parameterization of the rotation angles [178]. The superposition with highest 
volume overlap is reported out of the four maximization runs. In addition to shape, ROCS also 
attempts to maximize the overlap of „compatible‟ chemical features, which are also modeled as 
Gaussian functions. Among the several scoring functions reported by ROCS, we use the 
TanimotoCombo score, because it combines both the shape and chemistry superposition of the 
conformations into a single score. 
4.2.2 Generation of superposition models 
A solution of the ILP problem is a set of M conformations selected for being most mutually 
similar. Next we describe how these conformations are all superimposed. We superimpose M 
conformations by performing M-1 pairwise superpositions using ROCS [178] (see Section 4.2.1). 
One simple way to accomplish this is to designate one „reference‟ conformation and then 
 52 
superimpose the remaining M-1 conformations to it. However, it is more desirable to find the set 
of M-1 superpositions that maximize the sum of superposition scores. These M-1 pairwise 
superpositions correspond to the edges of the maximum spanning tree of the clique induced by 
the M conformations (Figure 14). For each edge of the maximum spanning tree, a superposition 
of the adjacent conformations is performed using ROCS [174]. Note that the order by which the 
superpositions are carried out is irrelevant. Note also the following transitive effect: if you 
superimpose A to B and B to C, then you automatically have A superimposed to C. 
 
Figure 14. (Left) Clique formed by 4 conformations. (Right) The maximum spanning tree of the clique defines 
the best 3 pairwise superpositions to overlay 4 conformations. See the text for details. 
4.3 APPLICATION TO C-MYC/MAX DISRUPTORS 
Here we report the application of the proposed methodology to modeling the bioactive 
conformations of known c-Myc/Max inhibitors, thus helping to delineate the shape and chemical 
features responsible for biological activity. There is no experimental structure of c-Myc in 
complex with small molecules. Our experimental dataset consists of 23 related compounds, of 
which 14 are actives and 9 inactives. The five compounds shown in Figure 15 were selected 
among the most active compounds to generate the model. We pre-generated at most 200 
conformations per compound using the software Omega2 2.4.3 (OpenEye Scientific Software) 
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[180]. Our program analyzed these conformations and outputted 30 superposition models (user-
specified parameter). 
 
Figure 15. Selected c-Myc/Max inhibitors and their in vitro binding affinity (Kd). 
We select the best model based on its ability to discriminate between active and inactive 
compounds. The area under the ROC (Receiver Operating Characteristic) curve provides a 
metric for model comparison. We use each superposition model as a query in the program 
ROCS. ROCS ranks order the 23 compounds in our dataset according to their overlay score 
(TanimotoCombo) to the model and then it computes the area under the ROC curve (AUC). The 
AUC ranged from 0.751 (model 27) to 0.896 (model 22) – see Figure 17. The average AUC over 
the 30 models was 0.799. The best model (model 22) is shown in Figure 16. 
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Figure 16. Superposition model 22. 
 
Figure 17. ROC curve of model 22 (the best) and model 27 (the worst) are 0.896 and 0.751, respectively. 
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Next we calculated the AUC obtained by using each one of the 5 conformations of model 
22, individually, as a query. The AUC ranged from 0.576 (Mol 1) to 0.777 (Mol 4) – see Figure 
18. Interestingly, using the entire ensemble of conformations as a query outperformed the results 
obtained by using each conformation individually. A possible explanation for that involves the 
density of atoms superimposed in the ensemble. Areas with high density of atoms weight more, 
and, therefore, molecules that do not overlay well in those areas are penalized. For instance, note 
in Figure 16 that the nitro group present in all 5 molecules overlay almost perfectly, hence this 
model penalizes a molecule if its nitro, or similar, group deviates from this „optimal‟ position. 
Likewise, the phenyl groups superimposed in the leftmost part of Figure 16 are all in the same 
plane, thus the model penalizes a molecule with phenyl, or similar, group lying out of that plane. 
 
 
Figure 18. Comparison of results obtained using the entire ensemble vs. individual conformations as queries. 
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Experimental Validation 
We used Model 22 (Figure 16) as ROCS query against the molecular libraries of the U. 
of Pittsburgh Center for Chemical Methodologies and Library Development (PITT CMLD) 
[181]. We selected 29 compounds, among the top hits, for experimental testing at Prof. 
Prochownik‟s Lab. At the time of this writing, the experiments were ongoing but we obtained 
confirmatory activity of at least one compound. Figure 19 shows the results from an 
Electrophoretic Mobility Shift Assay (EMSA) which quantitatively measured the dissociation of 
DNA from c-Myc/Max complex for different compound concentrations. 
 
Figure 19. (A) EMSA results. Recombinant c-Myc353-439 and full-length Max(S) were purified to 
homogeneity from E. coli and used at a final concentration of 30 nmol/L in the presence of the indicated 
concentration of compound. A 22 bp E-box-containing dsDNA oligonucleotide labeled on one strand with 
FAM was used at 10 nmol/L concentration in all reactions. B. Quantitative analysis. 
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5.0  STRUCTURE-BASED DRUG DESIGN: MIMICKING PROTEIN-PROTEIN 
INTERFACES WITH SMALL DESIGNED MOLECULES 
One way of designing small-molecule inhibitors of PPIs is to replicate the binding 
epitopes of one of the protein partners onto a small-molecule scaffold. In this chapter, we 
describe how the structure of the c-Myc/Max complex (PDB: 1NKP) was exploited to design 
compounds that mimic the localized binding interactions that Max makes with c-Myc. To 
achieve this goal, we developed a semi-automated protocol as described below. 
One potential problem with Max mimetic compounds is that since c-Myc is intrinsically 
disordered prior to complexation with Max, a small-molecule Max mimetic may not be able to 
overcome the high entropic barrier associated with inducing an ordered state on c-Myc. In 
anticipation of this potential problem, we adopted the following strategy: (i) we favor semi-rigid 
molecular designs with high degree of pre-organization of the binding groups, so as to reduce the 
entropic loss occurring upon binding; (ii) we target the hydrophobic regions of c-Myc since those 
tend to be less disordered; (iii) we choose a binding site confined to a short contiguous segment 
along the amino acid sequence of c-Myc. The latter implies that only a small segment of c-Myc 
will be required to fold upon binding, thus reducing the entropic cost that would otherwise be 
incurred if a larger portion of the protein was required to fold. This is supported by Hammoudeh 
el al. [28] findings that binding of c-Myc inhibitors at three independent sites induced only local 
conformational changes and preserved the overall disorder of c-Myc. 
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5.1 SELECTION OF BINDING SITE IN C-MYC 
We used the software FRED Receptor 2.2.5 (OpenEye Scientific Software) to identify candidate 
binding sites on c-Myc. The methodology implemented in FRED Receptor 2.2.5 allows for 
docking of small-molecule probes around the protein surface and then identifying binding sites 
as highly populated clusters of probes. The predicted binding sites are shown in Figure 20. We 
evaluated these sites using the criteria outlined in the previous section (Section 5.0 ). Note that 
site 2 requires the folding/packing of the helix-loop-helix segments, thus targeting this site is 
likely to be entropically expensive (unless the packing interactions are pre-existing, or accessible 
via soft modes, in free c-Myc, but there is no experimental evidence of that). Likewise, site 3 
appears between a helix and loop, and may also be entropically expensive. Besides that, sites 2 
and 3 are located away from the interface of the c-Myc/Max complex; targeting these sites may 
either disrupt c-Myc/Max through an allosteric effect or it may actually stabilize the complex. 
For instance, Jiang et al. [30] discovered stabilizers of the Max homodimer by targeting a site in 
Max corresponding to site 2 in c-Myc - presumably, the compounds stabilized the helix-loop-
helix packing in the bound form of the Max/Max complex. The only site remaining, i.e. site 1, 
appears to be a good site to target, since it is localized, hydrophobic, and situated in the c-
Myc/Max interface between the leucine zipper domains of c-Myc and Max. Therefore, we 
selected site 1 and we designed compounds to mimic the interactions of Max with c-Myc at this 
particular site. 
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Figure 20. Predicted small molecule binding sites (green mesh). Binding site 1, located in the leucine zipper 
domain, was selected. See text for details. 
5.2 MOLECULAR MIMICRY DESIGN PROTOCOL 
We developed a semi-automated protocol to facilitate the design of Max mimetic compounds. In 
this protocol, we specify what we want to mimic by pre-positioning molecular fragments in 3D 
space and/or providing desired pharmacophore features. Molecular mimicry is achieved by 
incorporating the fragments into the designed molecules while keeping their pre-determined 
positions, and also by satisfying the pharmacophore features provided. Fragments and 
pharmacophores, representing precisely the features to be mimicked, should be carefully selected 
to map the essential chemical features required for binding. For mimicking a protein-protein 
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interface, fragments and pharmacophores can be taken from hotspot residues, which can also be 
used to guide the selection of docked fragments. 
The goal was to generate molecules that incorporate the selected fragments and 
pharmacophores using small-molecule scaffolds (e.g. combinatorial chemistry scaffolds). 
However, scaffolds will seldom possess the exact geometry required to simultaneously connect 
multiple fragments and satisfy the pharmacophores. To overcome this limitation, we divided the 
process into two steps (see Figure 21). The first step was to anchor the scaffold on the binding 
site by any suitable means. We accomplished that by using one or more of the following 
methods: (1) docking the scaffold on the binding site; (2) directly connecting the scaffold to one 
pre-positioned fragment (shown in Figure 21, Step 1); (3) manually positioning the scaffold. 
Once the scaffold was anchored on the binding site, the next step was to build the 
scaffold side chains. We used fragment-based drug design techniques, fragment linking and 
fragment growing, to link a side chain to a nearby fragment, or to grow a fragment from a side 
chain to meet a nearby pharmacophore feature (see Figure 21, Step 2). Fragment linking and 
growing were accomplished using the software ReCore (BioSolveIT) [182], which returns, in a 
matter of seconds, fragments satisfying one or more bond vectors and pharmacophores. Note that 
scaffolds and fragments are annotated with attachment points (dummy atoms) to indicate the 
positions available for chemical linkage. The resulting molecules are derivatives of the employed 
molecular scaffolds, and the side chains of which are formed by the union of linkers to pre-
positioned fragments (fragment linking) or extensions that satisfy the pharmacophores (fragment 
growing). 
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Figure 21. Sketch of the protocol developed for mimicking protein-protein interfaces with small designed 
molecules. 
The algorithmic implementation of the proposed protocol is very challenging. We found 
a compromise between the convenience of automation and the human intervention required to 
design meaningful, synthetically feasible, compounds. While human intervention allows the user 
to incorporate prior knowledge and insights, which are currently impossible to automate, it also 
introduces subjectivity and, therefore, the results obtained may not be easily reproducible. The 
table below shows the division of steps between the computer and the user. 
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Table 1. Semi-automated implementation of the molecular mimicry design protocol. Division of steps between 
the computer and the user. 
User Intervention Computer Automation 
1. Decision of what to mimic, and selection of 
pre-positioned fragments and pharmacophore 
annotations accordingly; 
3. Scaffold anchoring/placement by docking or 
connecting the scaffold directly to pre-
positioned fragments; filtering and ranking of 
scaffold placements by interaction energy; 
2. Selection of small-molecule scaffolds; 5. Link/grow scaffold side chains to nearby 
fragments/pharmacophores and generate 
candidate molecules; ranking the candidate 
molecules by interaction energy; 
4. Selection of scaffolds‟ placements from the 
previous step and/or manual scaffold 
placement; 
7. Energy minimization of the molecules in the 
binding site. Re-start from step 1 if no 
satisfactory result was obtained. 
6. Selection of candidate molecules; optionally, 
replace a fragment using the software ReCore 
[182]. 
 
5.3 COMPOUNDS GENERATED USING THE PROPOSED PROTOCOL 
Figure 22 shows four examples of molecules designed to mimic the interactions that Max makes 
on the selected binding site in the leucine zipper domain of c-Myc. Note the shape 
complementarity of the molecules to the binding site. Besides, the molecules make similar 
contacts to c-Myc as those made by Max residues. In total, 18 molecules were designed using 
molecular scaffolds from the University of Pittsburgh Center for Chemical Methodologies and 
Library Development (CMLD) [181]. Compounds similar to the ones generated using the 
proposed protocol were identified through 3D similarity searches (OpenEye ROCS software) 
from the CMLD library and sent for experimental testing. 
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Figure 22. Molecules (yellow) designed to mimic the interactions that Max (cyan residues) makes with c-Myc 
(surface). 
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6.0  CONCLUSION 
6.1 CONTRIBUTIONS MADE TOWARDS FACILITATING THE DISCOVERY OF 
INHIBITORS OF PROTEIN-PROTEIN INTERACTIONS 
The discovery of small-molecule inhibitors of PPIs is a challenging endeavor pursued by 
industry and academic institutions. In this PhD dissertation, we aimed at assisting in increased 
productivity in the field through the following contributions: 
We presented a thorough review of current paradigms and strategies for discovering 
small-molecule modulators of PPIs (Chapter 2.0 ). We briefly introduced each approach, 
critically analyzed their advantages and disadvantages, and provided examples, taken from 
recent literature, of their successful applications. We also explained the therapeutic motivation 
for targeting the PPIs discussed in the examples. Since there is no single best drug discovery 
paradigm capable of tackling all drug targets, it is important to understand the strengths and 
weaknesses of each approach.  
In Chapter 3.0 , we presented an extensive analysis of the role of protein flexibility in 
molecular recognition and binding, and reviewed recent applications of ENM-based normal 
mode analyses to modeling the conformational changes of protein observed upon inhibitor 
binding. We classified the applications in two groups, namely: (1) generation of protein 
conformational ensembles for docking, and (2) coupled docking and deformation along normal 
modes. In addition, we proposed that pre-existing soft modes of motion, thermally accessible by 
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the protein, facilitate ligand binding. Chapter 3.0 was based on an article that has been recently 
accepted for publication in Protein Science [124]. 
We developed a new algorithm for generating putative models of the bioactive 
conformations of molecules in the absence of protein structure (Chapter 4.0 ). We showed how 
to validate and select the „best model‟, according to its ability to discriminate between known 
actives and inactives. Our method exploits a new insight: we can identify bioactive 
conformations by identifying the set of conformations that contains mutually similar members, in 
terms of their shape and the spatial distribution of their chemical features. To solve the problem 
we implemented an Integer Linear Programming formulation of the maximum edge weight 
clique problem. Using a model of the bioactive conformations of known c-Myc/Max inhibitors 
generated by this method, we have identified a new c-Myc/Max inhibitor confirmed 
experimentally and several other potential inhibitors to be tested experimentally. 
In Chapter 5.0 , we showed how the structure of a protein-protein complex can be 
exploited to design compounds that mimic the binding epitopes of one of the proteins. We 
designed compounds that mimic localized interactions of Max at the leucine zipper domain of c-
Myc, and identified similar compounds from the CMLD library that will be tested 
experimentally. 
6.2 FUTURE DIRECTION 
We envision some possible directions for future extensions and enhancements of the work herein 
presented. We believe the potential of ENMs for modeling protein flexibility coupled to ligand 
binding is an area that could be further exploited. The work reviewed in Chapter 3 provides 
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encouraging results, but it still lacks integration of ENMs with existing molecular docking 
software. As a step towards making ENMs more accessible to the general scientific community, 
we have developed ProDy [155], a Python-based software package that allows non-expert users 
as well as advanced software developers to take advantage of ENMs functionality with minimum 
effort [Credit: ProDy‟s primary developer was Dr. Ahmet Bakan]. 
One possible extension of ProDy concerns the implementation of more advanced 
algorithms for sampling protein conformations along relevant normal modes. The deformation of 
protein structures along normal modes generates unphysical geometries, which are usually 
corrected by energy minimization. However, energy minimization is computationally expensive 
and often causes significant distortions to the protein structure. An improved approach would 
consist of applying normal mode deformations only to Cα atoms and then making use of all-atom 
protein reconstruction algorithms [183-185]. These algorithms are capable of generating a full 
atomistic model of the protein structure from its reduced or coarse-grained representation, such 
as approximate position of backbone and/or side chains atoms. This approach promises to 
efficiently generate protein conformations guided by normal modes and free of unphysical 
geometries. 
In Chapter 4, we used an experimental dataset consisting of both active and inactive 
compounds to validate and select the best superposition model of the bioactive conformations of 
related c-Myc/Max inhibitors. However, in many practical circumstances, inactive compounds 
that share similar chemotypes may not be available to compute the area under the ROC curve 
utilized for model selection. To consider this scenario, the method could be extended to search 
for robust maximum edge weight cliques, which are insensitive to small changes in the weights. 
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The molecular mimicry design protocol presented in Chapter 5 could benefit from further 
automation, although we still expect some degree of human intervention be required to design 
meaningful, synthetically feasible, compounds. An integrated graphical user interface could, 
nevertheless, greatly facilitate the design process. As currently implemented, the attachment of 
fragments to a molecular scaffold, either by linking or growing, is unrestrained, but it would be 
useful to incorporate chemical rules to reflect the constraints imposed by synthetic organic 
chemistry. 
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